MENU

AVTX Stock Avalo Therapeutics (AVTX, $5.66) Moving Average Convergence Divergence (MACD) Histogram turned positive on July 17, 2025

A.I.dvisor
at Tickeron.com
Loading...
AVTX - Avalo Therapeutics
MACD signal
Bullish Trend
Odds of UP Trend
Tickeron
MACD signal
Price: $5.66
Daily change: +$0.81 (+16.7%)
Daily volume: 381.6K
Capitalization: $61.3M
Industry: Biotechnology
This is a Bullish indicator signaling AVTX's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 45 similar cases where AVTX's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

Momentum Indicator for AVTX turns positive, indicating new upward trend

AVTX saw its Momentum Indicator move above the 0 level on July 16, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 72 similar instances where the indicator turned positive. In of the 72 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for AVTX just turned positive on July 17, 2025. Looking at past instances where AVTX's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AVTX advanced for three days, in of 219 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 160 cases where AVTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 16 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AVTX broke above its upper Bollinger Band on August 04, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AVTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.925) is normal, around the industry mean (18.662). P/E Ratio (1.365) is within average values for comparable stocks, (54.033). AVTX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.909). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (217.391) is also within normal values, averaging (286.048).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
AVTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
A.I. Advisor
published General Information

General Information

a clinical stage biopharmaceutical company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
540 Gaither Road
Phone
+1 410 522-8707
Employees
19
Web
https://www.avalotx.com